|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-4-26
|
|
pubmed:abstractText |
The notion of combining immunomodulatory agents with the incretin exendin-4 (Ex-4) has seen considerable favor as a potential therapy for the reversal of type 1 diabetes in man. While the addition of Ex-4 provides modest improvement to the effectiveness of immunological-based monotherapies in reversing hyperglycemia in the nonobese diabetic (NOD) mouse, the mechanism of action underlying this effect remains controversial and formed the basis for this investigation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1873-460X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
163-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19217320-Animals,
pubmed-meshheading:19217320-Blood Glucose,
pubmed-meshheading:19217320-Cell Proliferation,
pubmed-meshheading:19217320-Diabetes Mellitus, Experimental,
pubmed-meshheading:19217320-Diabetes Mellitus, Type 1,
pubmed-meshheading:19217320-Female,
pubmed-meshheading:19217320-Hyperglycemia,
pubmed-meshheading:19217320-Hypoglycemic Agents,
pubmed-meshheading:19217320-Insulin,
pubmed-meshheading:19217320-Insulin-Secreting Cells,
pubmed-meshheading:19217320-Mice,
pubmed-meshheading:19217320-Mice, Inbred NOD,
pubmed-meshheading:19217320-Peptides,
pubmed-meshheading:19217320-Venoms
|
|
pubmed:articleTitle |
Exendin-4 treatment of nonobese diabetic mice increases beta-cell proliferation and fractional insulin reactive area.
|
|
pubmed:affiliation |
Department of Pathology, University of Florida, Gainesville, FL 32610, USA.
|
|
pubmed:publicationType |
Journal Article
|
